Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma

Leukemia Research

Volumn 37, Issue 4, 2013, Pages 410-415

  Bhaskar, Archana ^a,c   Gupta, Ritu ^a   Sreenivas, Vishnubatla ^b   Rani, Lata ^a   Kumar, Lalit ^a   Sharma, Atul ^a   Sharma, Om Dutt ^a   Sharma, Mehar Chand ^b   Thakur, Sonu Chand ^c  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Angiopoietin 2; Multiple myeloma; Progression free survival; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENALIDOMIDE; MELPHALAN; MESSENGER RNA; PREDNISOLONE; THALIDOMIDE; VASCULOTROPIN;

ANGIOPOIETIN 1 BLOOD LEVEL; ANGIOPOIETIN 2 BLOOD LEVEL; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; FIBROBLAST GROWTH FACTOR 2 BLOOD LEVEL; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA INDUCIBLE FACTOR 1ALPHA BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TREATMENT OUTCOME; VASCULOTROPIN BLOOD LEVEL;

ANGIOPOIETIN-2; BASE SEQUENCE; DISEASE PROGRESSION; DNA PRIMERS; HUMANS; MULTIPLE MYELOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875374634     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.12.014     Document Type: Article

References (30)

1. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
2. Pouysségur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
3. Rajkumar S.V., Leong T., Roche P.C., Fonseca R., Dispenzieri A., Lacy M.Q., et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000, 6:3111-3116.
4. Sezer O., Niemöller K., Jakob C., Jakob C., Kaufmann O., Zavrski I., et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000, 79:574-577.
5. Terpos E., Anargyrou K., Katodritou E., Kastritis E., Papatheodorou A., Christoulas D., et al. Greek Myeloma Study Group, Greece. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. Int J Cancer 2012, 130:735-742.
6. Joshi S., Khan R., Sharma M., Kumar L., Sharma A. Angiopoietin-2: a potential novel diagnostic marker in multiple myeloma. Clin Biochem 2011, 44:590-595.
7. Iwasaki T., Hamano T., Ogata A., Hashimoto N., Kitano M., Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002, 116:796-802.
8. Bhaskar A., Gupta R., Sreenivas V., Kumar L., Sharma A., Sharma M.C., et al. Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma. Leuk Lymphoma 2012, PMID: 23113684 [Epub ahead of print].
9. Neben K., Moehler T., Egerer G., Kraemer A., Hillengass J., Benner A., et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 2001, 7:2675-2681.
10. Andersen N.F., Standal T., Nielsen J.L., Heickendorff L., Borset M., Sørensen F.B., et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005, 128:210-217.
11. Giuliani N., Colla S., Lazzaretti M., Sala R., Roti G., Mancini C., et al. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myelomainduced angiogenesis. Blood 2003, 102:638-645.
12. Uneda S., Matsuno F., Sonoki T., Tniguchi I., Kawano F., Hata H. Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Haematologica 2003, 88:113-115.
13. Greipp P.R., San Miguel J., Durie B.G., Crowley J.J., Barlogie B., Bladé J., et al. International staging system for multiple myeloma. J Clin Oncol 2005, 23:3412-3420.
14. Bhatti S.S., Kumar L., Dinda A.K., Dawar R. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological and laboratory parameters. Am J Hematol 2006, 81:649-656.
15. Di Raimondo F., Azzaro M.P., Palumbo G., Bagnato S., Giustolisi G., Floridia P., et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000, 85:800-805.
16. Choi J.H., Ahn M.J., Jang S.J., Park C.K., Park Y.W., Oh H.S., et al. Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma. Int J Hematol 2002, 76:460-464.
17. Gianelli U., Vener C., Raviele P.R., Savi F., Somalvico F., Calori R., et al. VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders. Am J Clin Pathol 2007, 128:966-973.
18. Marković O., Marisavljević D., Cemerikić V., Vidović A., Perunicić M., Todorović M., et al. Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance. Med Oncol 2008, 25:451-457.
19. Lobov I.B., Brooks P.C., Lang R.A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002, 99:11205-11210.
20. Loges S., Heil G., Bruweleit M., Schoder V., Butzal M., Fischer U., et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 2005, 23:1109-1117.
21. Hata K., Nakayama K., Fujiwaki R., Katabuchi H., Okamura H., Miyazaki K. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 2004, 93:215-222.
22. Theodoropoulos V.E., Lazaris ACh., Sofras F., Gerzelis I., Tsoukala V., Ghikonti I., et al. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004, 46:200-208.
23. Isobe T., Aoyagi K., Koufuji K., Shirouzu K., Kawahara A., Taira T., et al. Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric cancer. Int J Clin Oncol 2012, PMID: 22350022 [Epub ahead of print].
24. Hoffmann A.C., Mori R., Vallbohmer D., Brabender J., Klein E., Drebber U., et al. High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia 2008, 10:674-679.
25. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59:5830-5835.
26. Andersen S., Donnem T., Al-Shibli K., Al-Saad S., Stenvold H., Busund L.T., et al. Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2. PLoS ONE 2011, 6:e19773.
27. Porkholm M., Bono P., Saarinen-Pihkala U.M., Kivivuori S.M. Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased non-relapse mortality after pediatric hematopoietic SCT. Bone Marrow Transplant 2012, PMID: 22659681 [Epub ahead of print].
28. Prince H.M., Hönemann D., Spencer A., Rizzieri D.A., Stadtmauer E.A., Roberts A.W., et al. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood 2009, 113:4819-4820.
29. Ribbatti D. Tyrosine kinase inhibitors as antiangiogenic drugs in multiple myeloma. Pharmaceuticals 2010, 3:1225-1231.
30. Huang H., Lai J.Y., Do J., Liu D., Li L., Del Rosario J., et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 2011, 17:1001-1011.